Login / Signup

Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.

Muhammed Osman CorbaliAhmet Emre Eskazan
Published in: Future oncology (London, England) (2020)
Keyphrases
  • acute myeloid leukemia
  • acute lymphoblastic leukemia
  • diffuse large b cell lymphoma
  • multiple myeloma
  • hodgkin lymphoma
  • combination therapy
  • replacement therapy